Do Aspirin Users Have Fewer Metastases at Colorectal Cancer Diagnosis? Swedish Data on 81,000 Patients

In this article
Data on 81,000 Patients from Sweden: Fewer Metastases at Diagnosis in Aspirin Users, Especially in the Right Colon
A Swedish nationwide registry study published in the British Journal of Cancer on 21 November 2026 showed that patients who were taking regular low-dose aspirin when they were diagnosed with colorectal cancer were less likely to have distant metastases (stage IV) at diagnosis. In the study of 81,269 patients, the adjusted odds ratio (OR) was 0.86 (95% CI 0.82–0.90); the association was stronger for right-sided colon tumours (OR 0.79). This is an interesting research signal that varies with tumour location. However, the study is observational; it does not prove that aspirin prevents metastasis, and nobody should start taking aspirin on the basis of this result. I have previously discussed the place of aspirin in colorectal cancer in my articles on aspirin in PI3K-mutated colorectal cancer, which cancers regular aspirin may reduce the risk of and the difference between right- and left-sided colon cancer.
- What was investigated? 81,269 patients diagnosed with colorectal cancer in Sweden between 2008 and 2021; according to prescription records, those dispensed at least 365 tablets of low-dose aspirin (75 or 160 mg) in the 2 years before diagnosis were classed as "current users" (19%). The outcome was distant metastasis at diagnosis (23%).
- Finding: Adjusted OR 0.86 in current users; 0.87 in past users. 0.79 in the right colon, 0.84 in the colon as a whole, 0.90 in the rectum. According to the abstract, there was no clear association in the left colon. As a rough calculation, this corresponds to a difference of about 2–3 percentage points in the proportion of patients diagnosed with metastases.
- Limitations: Observational design; no data on over-the-counter aspirin, other blood thinners, family history or lifestyle; it is not known whether the drug was actually taken. Causality cannot be established.
- In practice: Aspirin should not be started to prevent cancer or metastasis. If aspirin is being taken for cardiovascular reasons, it should be continued as advised by the doctor. The effective way to prevent colorectal cancer is screening.
Why does this matter?
Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related loss of life (colon and rectal cancer: symptoms, stages and treatment). About one in five patients already has distant metastases at diagnosis; in this study the figure was 23%. Whether or not metastases are present at diagnosis is the most important factor determining the goal of treatment and survival. That is why a cheap, widely used drug that might reduce the risk of metastasis attracts the interest of both doctors and the public.
The link between aspirin and colorectal cancer has been researched for a long time. Long-term analyses of older randomised cardiovascular trials had suggested that colorectal cancer incidence and spread might be reduced in people taking aspirin (the effect of aspirin in preventing bowel cancer). The Swedish randomised ALASCCA trial, published in the New England Journal of Medicine in 2025, showed that 160 mg of aspirin daily roughly halved the risk of recurrence in patients with resected colorectal cancer carrying alterations in the PI3K pathway (aspirin and the risk of recurrence). On the other hand, in the ASPREE trial in healthy people aged 70 and over, aspirin gave no benefit with regard to cancer and increased the risk of bleeding. In other words, the benefit of aspirin is not the same for everyone.
- Yes: It is one of the largest studies to examine metastasis at diagnosis in detail on a national scale, using prescription records and by tumour location. The stronger association found in the right colon is striking.
- No: It is not the first study to examine the link between aspirin and metastasis in colorectal cancer; pooled analyses of older randomised trials and other observational studies had given similar signals.
- Not yet: No randomised trial has shown that aspirin prevents metastasis. No guideline recommends aspirin to prevent metastasis in colorectal cancer.
Does aspirin prevent metastasis in colorectal cancer?
On current evidence, no, that cannot be said. In Sweden's registry study of 81,269 patients, those taking regular low-dose aspirin were less likely to have metastases at diagnosis, but this is an observational association. No randomised trial has shown that aspirin prevents metastasis, and aspirin should not be started for this purpose. Only randomised trials can give a definitive answer.
The study was carried out by researchers from the Karolinska Institutet and Karolinska University Hospital; the authors include Anna Martling, who was also one of the leaders of the ALASCCA trial. The data were obtained by linking the Swedish Colorectal Cancer Registry with the national prescription, patient, cancer and population registers. The strength of such national registries is that they cover almost all patients and that prescription information is based on pharmacy records rather than on patients' recall.
Figure 1 · Study flow
Swedish national registries, 2008–2021
What was found?
After accounting for factors such as age, sex, year of diagnosis, education level, diabetes, hypertension, cardiovascular disease, inflammatory bowel disease and gastrointestinal bleeding, current aspirin users had a 14% lower likelihood of distant metastasis at diagnosis (OR 0.86; 95% CI 0.82–0.90). Interestingly, a similar association was seen in past users who had not taken aspirin in the previous two years (OR 0.87; 0.81–0.94). In the crude data, liver metastases were seen in 13% of aspirin users and 18% of non-users; metastases in more than one organ in 10% versus 14%.
The association was strongest in the right colon: for right-sided colon tumours, the OR was 0.79 (0.74–0.86) in current users and 0.77 (0.69–0.87) in past users. In the rectum the association was weaker (OR 0.90; 0.82–0.98) and was not seen in past users. The abstract of the paper states that there was no clear association in the left colon. Looking at duration of use, there was an association for use of less than 3 years (OR 0.81) and 5 years or longer (OR 0.85), but not a significant one for 3–5 years; this inconsistency suggests there is no clear duration–effect relationship. Dose analyses were similar to the main results.
Distant metastasis at diagnosis: adjusted odds ratios
Compared with non-users of aspirin; values below 1 indicate lower odds.
Adjusted for age, sex, year of diagnosis, education, diabetes, hypertension, cardiovascular disease, inflammatory bowel disease and gastrointestinal bleeding. Observational data; does not show causality. Source: Shahrivar et al., British Journal of Cancer, 2026.
Relative and absolute effects need to be considered together. An OR of 0.86 means a relative reduction of 14% in the odds. In a population where around 23% have metastases at diagnosis, a rough calculation suggests this corresponds to a difference of 2–3 in every 100 patients being diagnosed at an earlier stage. This is a small difference, though potentially meaningful at population level; still, because the study is observational, it is uncertain whether it reflects a real effect.
In a secondary analysis, the researchers also looked at lymph node involvement (stage III) in patients without metastases. No overall association was seen in current users; there was a weak association in past users and in long-term users with right-sided colon cancer (OR 0.87–0.91). In other words, the signal is clearest for distant metastasis, particularly in the right colon.
Why the right colon?
The right and left colon have different embryological origins and different molecular features. Right-sided colon tumours are more often microsatellite instable (MSI), BRAF-mutated and mucin-producing, and they also have a worse course in the metastatic stage (what you should know about colon and rectal cancer). Fusobacterium nucleatum, a bacterium of oral origin, is also found more often in right-sided colon tumours and has been linked to an aggressive course (Fusobacterium and aggressive colon cancer, the oral microbiome and colorectal cancer). Laboratory studies suggest that aspirin may suppress this bacterium.
The strongest explanation for a possible effect of aspirin on metastasis, however, is platelets. Tumour cells that enter the bloodstream become coated with platelets, which shields them from the immune system and makes it easier for them to attach to the vessel wall. Low-dose aspirin permanently suppresses platelet function. It can also reduce inflammation and tumour growth via the COX-2 and prostaglandin pathway (the microbiota and colorectal cancer). However, this study did not test these mechanisms; they are possible explanations.
Figure 2 · Possible biological explanations
How might aspirin affect metastasis?
How reliable are these results?
The study's strengths are clear: a large, national dataset covering almost all patients, with prescription information taken from pharmacy records. However, the known limitations of observational studies apply here too. People who take aspirin see a doctor more often because of cardiovascular disease; this may lead to symptoms being noticed earlier and cancer being caught at an earlier stage. Because aspirin increases bleeding, it may also make hidden bleeding appear earlier. The authors argue that the similar association in past users and the variation of the effect by location weaken these explanations; this is a reasonable argument, but it does not completely rule out bias.
In addition, there is no information on over-the-counter aspirin use, other blood thinners such as clopidogrel, family history, smoking, diet or physical activity. Being dispensed a prescription does not mean the drug was taken regularly. The fact that the left colon results are worded differently in different sections of the paper also calls for careful reading.
Figure 3 · Why is an observational association not proof of causality?
Four possible sources of error
What it means in practice for patients
Do not start taking aspirin on the basis of this study. Even low-dose aspirin can cause serious side effects such as stomach and bowel bleeding or bleeding in the brain; this risk rises with age. If you take aspirin because you have had a heart attack or stroke, do not stop it without talking to your doctor.
The proven way to avoid being diagnosed with metastatic colorectal cancer is screening. In Türkiye, the national screening programme offers a faecal occult blood test to people aged 50–70, and colonoscopy is performed depending on risk (what is a colonoscopy?, how can I protect myself from colorectal cancer?). Screening with blood tests is also developing (early diagnosis with a blood test, fragmentomics and methylation). It is important to remember that colorectal cancer is also increasing in young people, and to seek medical advice without delay for symptoms such as blood in the stool, a change in bowel habits or unexplained anaemia (colon cancer in young people, haemorrhoids and colon cancer).
For patients already diagnosed with colorectal cancer, the role of aspirin is a separate matter. The ALASCCA trial showed that aspirin reduced recurrence in resected patients with alterations in the PI3K pathway; so for these patients, molecular testing of the tumour and the question of aspirin can be discussed with the doctor. In metastatic disease, treatment, surgery and systemic options should be planned individually (ctDNA in liver metastases, transplantation for liver metastases).
Questions you can ask your doctor
- What are the benefits and the bleeding risk of taking aspirin for me?
- If I take aspirin for cardiovascular reasons, does this mean anything with regard to colorectal cancer?
- Given my age and family history, which colorectal cancer screening test should I have, and how often?
- If I have been diagnosed with colorectal cancer, has my tumour been tested for PI3K pathway alterations, and is aspirin an option for me?
- Which symptoms should prompt me to seek medical advice without delay?
- "Aspirin stops colon cancer from spreading." Not proven. This study shows an observational association; causality can only be established by randomised trials.
- "Low-dose aspirin is harmless and anyone can take it." No. There is a risk of gastrointestinal and brain bleeding, which increases with age. In the trial in people over 70, no cancer benefit was seen.
- "If I take aspirin, I don't need screening." No. Regardless of aspirin use, screening is the most effective way to prevent colorectal cancer.
- "A 14% reduction is a big difference." It is a relative difference; in absolute terms it corresponds roughly to a difference of 2–3 people per 100 patients, and it is uncertain whether it is a real effect.
- "I should stop or increase the aspirin I take for my heart because of cancer risk." No. Your doctor decides on the dose and duration based on your cardiovascular risk.
To read studies like this correctly, it is important to know the difference between observational and randomised studies (what is a clinical trial?). For emergencies that can arise in advanced colorectal cancer, see my article on bowel obstruction.
Frequently Asked Questions
- Does aspirin prevent metastasis in colorectal cancer?
- Not proven. In Sweden's registry study of 81,269 patients, low-dose aspirin users were less likely to have metastases at diagnosis; but this is an observational association and does not show that aspirin prevents metastasis.
- Why is the effect of aspirin clearer in the right colon?
- This is not known for certain. Possible explanations include the different molecular make-up of right-sided colon tumours, the bacterium Fusobacterium nucleatum, which is more common in this region, and platelet-related mechanisms; these are still hypotheses.
- Should I take aspirin to protect myself from colorectal cancer?
- No, it is not recommended for this purpose alone. Because of the bleeding risk, the decision on aspirin should be made with your doctor, taking cardiovascular risk into account. The most effective way to prevent colorectal cancer is regular screening.
- If I have been diagnosed with colorectal cancer, will aspirin help?
- In resected patients with alterations in the PI3K pathway, the randomised ALASCCA trial showed that aspirin reduced the risk of recurrence. In other patients, a benefit has not been proven; the decision should be made together with your doctor.
Glossary
- Synchronous metastasis
- Spread to other organs detected at the time the cancer is diagnosed.
- Odds ratio (OR)
- The ratio of the odds of an event occurring in two groups; a value below 1 means lower odds.
- Confidence interval
- The range within which the true value most likely lies.
- Observational study
- A study in which the researcher does not assign treatment but examines existing data; it shows association, not causality.
- Randomised trial
- A study in which participants are allocated to groups by chance; the most reliable study type for establishing causality.
- Right colon
- The part of the large bowel that includes the caecum, ascending colon and the first part of the transverse colon.
- Platelet
- A blood cell that enables blood clotting; it may also play a role in tumour spread.
- COX-2
- An enzyme that produces prostaglandins, which play a role in inflammation and tumour growth; aspirin suppresses it.
- PI3K pathway
- A signalling pathway that regulates cell growth; aspirin may be more effective in tumours carrying alterations in it.
- Detection bias
- Earlier detection of a disease in one group because that group is examined more often.
DROZDOGAN Academy Commentary
The link between aspirin and colorectal cancer is one of the longest-running and most debated topics in oncology. This study adds an interesting piece to the picture: the effect may differ depending on where the tumour is located.
⚡ Why it matters
Metastasis at diagnosis is one of the most important factors determining survival in colorectal cancer. The finding that a cheap, widely used drug is associated with this likelihood opens the door to new research, particularly on the right colon and on platelet–tumour interaction.
✅ Strengths
81,000 patients on a national scale; prescription data taken from pharmacy records; detailed analyses by tumour location, duration of use and dose; an experienced team that led ALASCCA.
⚠️ Limitations
Observational design; no data on over-the-counter aspirin, other blood thinners, family history or lifestyle; adherence unknown. Detection bias cannot be fully ruled out. The duration–effect relationship is not consistent, and the left colon results are worded differently in the paper. The effect size is small in absolute terms.
🩺 In practice
I do not recommend aspirin to my patients to prevent cancer or metastasis. To those taking aspirin for cardiovascular reasons, I say they should not stop it. In my patients with resected colorectal cancer, after ALASCCA, I discuss testing the tumour for the PI3K pathway and, in suitable patients, aspirin. And I remind everyone of age-appropriate screening.
❓ Open questions
Is the association in the right colon a real biological difference, or is it related to right-sided colon tumours causing symptoms later? Is the effect driven by platelets, bacteria or inflammation? Is the benefit of aspirin greater in certain molecular subgroups (PI3K, MSI, BRAF)? Is a personalised approach that balances benefit against bleeding risk possible?
Bottom line: A striking research signal, but not a clinical recommendation. Aspirin has not been proven as a drug to use to prevent metastasis in colorectal cancer. Today the strongest means of prevention is screening, and for patients who have been diagnosed, evidence-based personalised treatment.
- This article was prepared in November 2026.
- The study information is taken from the text of the paper published in the British Journal of Cancer on 21 November 2026; some raw figures in the tables and the detailed odds ratios for the left colon could not be accessed. The absolute difference estimate is a rough calculation based on the overall metastasis rate in the paper.
- Information on other studies is based on the references below.
- The diagrams are simplified. The Academy commentary is my own. This article is not medical advice; make decisions about your medicines together with your doctor.
References
- Shahrivar M, Dietrich CE, Glimelius B, Martling A, … Nordenvall C. Low-dose aspirin use and the risk of synchronous metastatic colorectal cancer: results from a population-based study. Br J Cancer 2026. doi
- Martling A, et al. Low-dose aspirin for PI3K-altered localized colorectal cancer (ALASCCA). N Engl J Med 2025. ascopost.com
- Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379:1591-1601. doi
- McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly (ASPREE). N Engl J Med 2018;379:1519-1528. doi
- US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: recommendation statement. JAMA 2022;327:1577-1584. doi
Was this article helpful?
Your feedback helps us improve our content.




